Psychiatry · Medical Literature
Rosiglitazone Adjunct to Sertraline for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.
Abstract
Insufficient responses to available treatments for major depressive disorder (MDD) underscores the necessity for innovative therapeutic strategies. This study investigated the efficacy of adjunctive rosiglitazone, an antidiabetic agent with neuroprotective and anti-inflammatory effects, for MDD. In this 6-week randomized, parallel-group, double-blind, placebo-controlled clinical trial, patients with MDD were assigned to receive sertraline along with either rosiglitazone 2 mg or a matched placebo q12 h. Participants were evaluated using the Hamilton depression rating scale (HDRS) at baseline and weeks 2, 4, and 6. The difference in its score changes to the endpoint was the primary outcome. Side effects were documented as well. The participants had comparable baseline characteristics. A significant time -treatment interaction effect was observed for HDRS scores ( η P 2 = 0.052), with the rosiglitazone group experiencing significantly greater reductions at weeks 2 (Cohen's d = 0.507), 4 (Cohen's d = 0.556), and 6 (Cohen's d = 0.541) compared to the placebo group. Additionally, the rosiglitazone group demonstrated significantly higher response rates until weeks 4 (50.0% vs. 24.2%) and 6 (84.4% versus 51.5%). By week 6, the remission rate was nonsignificantly higher in the rosiglitazone group (18.8%) than in the placebo group (9.1%). Side effect frequencies were comparable. In conclusion, rosiglitazone was beneficial for depressive symptoms of patients with MDD safely and tolerably. Further long-term, large-scale studies are recommended to confirm this evidence. Trial Registration: ClinicalTrials.gov identifier: IRCT20090117001556N152.
Clinical relevance
Major depressive disorder remains undertreated, with a substantial proportion of patients failing to achieve adequate response or remission with standard antidepressant monotherapy, underscoring the urgent need for evidence-based augmentation strategies. This trial investigates rosiglitazone — a thiazolidinedione PPAR-γ agonist with documented neuroprotective and anti-inflammatory properties — as an adjunct to sertraline, targeting neuroinflammatory and metabolic pathways implicated in MDD pathophysiology. Given the growing recognition of inflammation and insulin resistance as contributors to treatment-resistant depression, these findings are clinically timely and relevant for psychiatrists managing patients with inadequate antidepressant responses.
Key findings
1. A statistically significant time-by-treatment interaction was observed for Hamilton Depression Rating Scale (HDRS) scores (ηp² = 0.052), indicating that rosiglitazone 2 mg q12h augmentation of sertraline produced superior depressive symptom reduction trajectories compared to sertraline plus placebo over 6 weeks. 2. Between-group effect sizes for HDRS score reductions were in the moderate range at all assessment time points: Cohen's d = 0.507 at week 2, Cohen's d = 0.556 at week 4, and Cohen's d = 0.541 at week 6, favoring the rosiglitazone group. 3. Response rates were significantly higher in the rosiglitazone group versus placebo at week 4 (50.0% vs. 24.2%) and week 6 (84.4% vs. 51.5%), representing clinically meaningful absolute risk differences of 25.8 and 32.9 percentage points, respectively. 4. Remission rates at week 6 were numerically higher in the rosiglitazone group (18.8%) compared to placebo (9.1%); however, this difference did not reach statistical significance, likely reflecting inadequate power to detect remission differences. 5. The frequency and profile of side effects were comparable between the rosiglitazone and placebo groups, suggesting a favorable short-term tolerability and safety profile for adjunctive rosiglitazone at this dose and duration. 6. Clinically meaningful antidepressant benefits were detectable as early as week 2 (Cohen's d = 0.507), suggesting a potentially rapid onset of augmentation effect with rosiglitazone.
Practice implications
Adjunctive rosiglitazone (2 mg q12h) may be considered as an investigational augmentation strategy in adult patients with MDD experiencing suboptimal response to standard SSRI therapy, particularly those with comorbid metabolic dysregulation or elevated inflammatory burden where PPAR-γ agonism may confer additional mechanistic benefit; however, routine clinical adoption should await replication in larger, longer-duration trials. Clinicians considering this approach must carefully weigh rosiglitazone's established cardiovascular and hepatic risk profile — including its FDA black-box history regarding myocardial ischemia — against potential psychiatric benefit, necessitating thorough cardiovascular risk stratification, baseline LFTs, and exclusion of patients with heart failure or active hepatic disease before initiation. Given the nonsignificant remission difference and the short 6-week trial duration, this evidence is currently hypothesis-generating rather than practice-changing, and psychiatrists should prioritize enrollment in confirmatory large-scale RCTs while continuing to use guideline-supported augmentation agents (e.g., atypical antipsychotics, lithium, or thyroid hormone) in treatment-resistant MDD.